In 2023, the sales of modulators of the genital system and sex hormones in Norway were recorded at 11.5 US Dollars Per Capita. The forecast data from 2024 onward show a gradual decline, with values expected to be 11.4 in 2024, 11.3 in 2025, 11.2 in both 2026 and 2027, and 11.1 in 2028. This indicates a year-on-year decrease of approximately 0.87% from 2023 to 2024, and similar incremental decreases can be observed through 2028. The Compound Annual Growth Rate (CAGR) over the next five years is anticipated to be negative, indicating a shrinking market.
Factors driving this decline could include increased competition from alternative treatments, shifts in healthcare policies or patient preferences, and market saturation. Additionally, the introduction of generic drugs could put downward pressure on prices.
Future trends to watch for:
- Technological advancements in drug delivery systems which might rejuvenate market interest.
- Regulatory changes that could affect market dynamics.
- Potential breakthroughs in related medical fields that could introduce new, more effective treatment options.
- Societal and demographic changes impacting healthcare priorities.
